ReviewNature reviews. Cancer2016
Inducing stable reversion to achieve cancer control.
Review in Nature reviews. Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Control of Cellular Differentiation Trajectories for Cancer Reversion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Lethal effects of mitochondria via microfluidics.Bioengineering & translational medicine · 2023Article
- Critical transition and reversion of tumorigenesis.Experimental & molecular medicine · 2023Review
- Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy.International journal of molecular sciences · 2023Review
- Exosome-mediated delivery of SCD-1 siRNA promoted the death of anaplastic thyroid carcinoma cells via regulating ROS level.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentation.Frontiers in immunology · 2022Article
- Deciphering the molecular mechanism of the cancer formation by chromosome structural dynamics.PLoS computational biology · 2021Article
- Reversion of tumor hepatocytes to normal hepatocytes during liver tumor regression in an oncogene-expressing transgenic zebrafish model.Disease models & mechanisms · 2019Article
- A spotlight on bacterial mutations for 75 years.Nature · 2018Article
- Identification of protein kinase inhibitors to reprogram breast cancer cells.Cell death & disease · 2018Article
- Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors.Journal of experimental & clinical cancer research : CR · 2018Article
- Cancer reversion with oocyte extracts is mediated by cell cycle arrest and induction of tumour dormancy.Oncotarget · 2018Article
- Gallnuts: A Potential Treasure in Anticancer Drug Discovery.Evidence-based complementary and alternative medicine : eCAM · 2018Review
- Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells.International journal of nanomedicine · 2018Article
- TCTP as a therapeutic target in melanoma treatment.British journal of cancer · 2017Article
- Attractor landscape analysis of colorectal tumorigenesis and its reversion.BMC systems biology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
How can we stop cancer progression? Current strategies depend on modelling progression as the balanced outcome of mutations in, and expression of, tumour suppressor genes and oncogenes. New treatments emerge from successful attempts to tip that balance, but secondary mutational escape from those treatments has become a major impediment because it leads to resistance. In this Opinion article, we argue for a return to an earlier stratagem: tumour cell reversion. Treatments based on selection and analysis of stable revertants could create more durable remissions by reducing the selective pressure that leads to rapid drug resistance.
Indexed as
Identifiers
27458638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.